PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
LaserOptek posted a revenue recovery and narrowing losses in the first half of 2026, but the record net loss of 2025 and overhangs from U.S. litigation and share dilution from a rights offering remain in place.
First-half 2026 revenue rose to KRW 15.1 billion (up 65.3% year-on-year), with both operating and net losses narrowing from a year earlier.
Full-year 2025 revenue fell to KRW 25.7 billion year-on-year, with an operating loss of KRW 12.0 billion and a net loss of KRW 10.7 billion, the largest since listing.
Litigation with U.S. competitor Strata Skin Sciences continues; Strata was delisted from Nasdaq around March 2026, and LaserOptek filed counterclaims.
A rights offering conducted between January and April 2026 raised KRW 11.8 billion, but controlling shareholders subscribed to only about 10% of their allotment, raising dilution concerns.
The company launched VASCURA 589, described as the world's first high-power solid-state 589nm vascular laser, and aims to file for U.S. FDA approval in the second half of 2026.
LaserOptek was founded in 2000 and listed on KOSDAQ in February 2024 as a medical device maker built on proprietary laser technology.
The company initially developed lasers for semiconductor and automotive manufacturing before entering the aesthetic laser market with LOTUS and HELIOS in 2005, and it laid the groundwork for overseas expansion by obtaining U.S. FDA and European CE certifications in 2009.
Its business is split into two segments, skin aesthetic devices and disease treatment devices; as of the third quarter of 2025, skin aesthetic devices accounted for about 79.6% of revenue, while disease treatment devices based on the solid-state UVB laser PALLAS series, used for vitiligo, psoriasis and atopic dermatitis, made up about 8.8%.
Flagship aesthetic products include HELIOS 785, which uses picosecond and Q-switched Nd:YAG lasers for pigment and scar treatment, and SCULPIO, which combines pico-laser and lifting functions, and the company recently added VASCURA 589 to its portfolio, described as the world's first device to achieve high output at the 589-nanometer wavelength in a solid-state laser using Raman scattering.
By region, as of 2024 domestic sales accounted for about 47% of revenue, Asia 25%, Europe 13%, and North America 5%, reflecting a mixed domestic-export structure, and the company maintains a sales network across roughly 50 countries.
In the disease-treatment device market, Nasdaq-listed Strata Skin Sciences long held an oligopoly with pulsed dye laser (PDL)-based products in the vascular and psoriasis treatment space, and LaserOptek is challenging that structure with differentiated solid-state laser products.
Production takes place at its facility in Seongnam, Gyeonggi Province, and the company has pursued capacity expansion through a headquarters relocation and remodeling of its existing production lines.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.9B | -₩2.3B | −59.2% |
| 2025Q3 | ₩9.9B | -₩3B | −30.1% |
| 2025Q4 | ₩6.7B | -₩4.5B | −67.5% |
| 2026Q1 | ₩6.4B | -₩2B | −30.7% |
| 2026Q2 | ₩8.8B | -₩1B | −11.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩30B | ₩2.5B | ₩2.8B | 8.4% | 23.4% | 108.9% |
| 2023 | ₩34.4B | ₩4.5B | ₩16,781,543 | 13.0% | 0.1% | 48.5% |
| 2024 | ₩33B | -₩200M | -₩800M | −0.6% | −2.6% | 48.9% |
| 2025 | ₩25.7B | -₩12B | -₩10.7B | −46.9% | −48.4% | 64.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Annual revenue rose from KRW 30.0 billion in 2022 to KRW 34.4 billion in 2023, continuing a double-digit growth trend, before slipping to KRW 33.0 billion in 2024 and then falling sharply to KRW 25.7 billion in 2025.
Operating profit swung from a surplus of KRW 4.5 billion in 2023 (a 13.0% operating margin) to a loss of KRW 0.2 billion in 2024, widening to a loss of KRW 12.0 billion in 2025.
Net income attributable to owners followed a similar pattern, from a surplus of KRW 2.8 billion in 2022 and a roughly break-even 2023 to losses of KRW 0.8 billion in 2024 and KRW 10.7 billion in 2025.
On a quarterly basis, revenue peaked at KRW 9.87 billion in the third quarter of 2025, fell to KRW 6.66 billion in the fourth quarter, then recovered to KRW 6.36 billion and KRW 8.79 billion in the first and second quarters of 2026, respectively.
The operating loss widened to KRW 4.49 billion in the fourth quarter of 2025 before narrowing for three consecutive quarters to KRW 1.95 billion and KRW 0.99 billion in the first and second quarters of 2026.
The net loss attributable to owners also improved markedly, from KRW 2.62 billion and KRW 2.55 billion in the third and fourth quarters of 2025 to KRW 1.18 billion and KRW 0.77 billion in the first and second quarters of 2026.
Behind this earnings weakness lies litigation with a U.S. competitor that began in August 2024, which is understood to have caused North American revenue from disease-treatment devices to plunge from KRW 5.1 billion in 2024 to KRW 1.3 billion in 2025.
Reports from that period also noted the gross margin declining from the mid-40% range to around 40%.
In the first half of 2026, sales of the pigment-treatment device HELIOS 785 rose 154.9% year-on-year to KRW 5.2 billion, while PALLAS and PALLAS Premium sales grew 43.5% to KRW 1.2 billion, driving the earnings improvement.
The global aesthetic and medical laser market is expected to see medium- to long-term growth, driven by rising demand for cosmetic procedures and the spread of energy-based device (EBD) trends.
Citing market research data, one report projected that the global skin and aesthetic medical device market, including lifting devices, would grow from USD 17.8 billion in 2024 to USD 145.7 billion by 2030.
The vascular treatment laser segment has been dominated by pulsed dye laser (PDL)-based products for decades, and LaserOptek is challenging this structure with its solid-state VASCURA 589.
In the disease-treatment device market, Nasdaq-listed Strata Skin Sciences had competed with its XTRAC line of products for psoriasis and vitiligo treatment, but it was delisted from Nasdaq around March 2026 amid financial difficulties, altering the competitive landscape.
Domestically, LaserOptek is regarded as one of the few homegrown laser makers to have built in-house design capabilities starting from semiconductor and industrial lasers, and it maintains an export-heavy business structure with a sales network spanning roughly 50 countries.
Some brokerages have noted that in an aesthetic laser market where large global players have been relatively slow to launch new products, a domestic company with proprietary technology and a diverse product portfolio holds an attractive market position.
The company is treating 2026 as the founding year of an earnings rebound, focusing on expanding its new product portfolio and normalizing overseas sales operations. VASCURA 589, launched domestically, is targeted for expanded sales in the second half along with a U.S.
FDA filing within the year, with Korean regulatory certification obtained in the first quarter of 2026 expected to be followed by a North American market entry by year-end or in early 2027.
In the disease-treatment segment, the key variable is whether U.S. sales of PALLAS Premium, which had been curtailed by litigation, can resume, with the removal of a competitor's product name from insurance code descriptions seen as a potential turning point.
The company is reportedly developing three new products: a lifting device, a thulium fiber laser for urology, and a Raman laser-based disease-treatment device.
On the production side, the company has expanded its production lines through remodeling at its Seongnam facility to prepare capacity for higher volumes of new products.
Hana Securities characterized 2026 as a period of top-line recovery, assessing that a return to growth would be possible from 2027 once exports of major products normalize.
However, this outlook still depends on multiple variables, including the outcome of litigation, certification timelines, and the pace of overseas channel recovery.
Having posted a net loss in 2025 and continuing to record losses into 2026, LaserOptek is in a position where a price-to-earnings ratio cannot be calculated in the conventional sense.
Its price-to-book ratio trades in a range that reflects a premium over net asset value, a result that also partly stems from the recent decline in net assets caused by accumulated losses. On dividends, the company has had no payout track record in recent years, leaving no comparable basis for a dividend yield.
While quarterly losses have shown a gradual narrowing trend since 2026, this has not yet translated into a full-year profit turnaround, so valuation metrics remain subject to change depending on whether the earnings improvement continues.
The increase in total shares outstanding from the rights offering completed in early 2026 should also be factored in when interpreting per-share metrics.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Operating losses of KRW 1.95 billion and KRW 0.99 billion in the first and second quarters of 2026 narrowed markedly from KRW 4.49 billion in the fourth quarter of 2025. Net losses attributable to owners over the same period, KRW 1.18 billion and KRW 0.77 billion, also showed continued improvement.
Revenue in the second quarter of 2026 reached KRW 8.79 billion, up sharply from KRW 3.90 billion a year earlier, signaling a recovery in top-line scale.
The company launched VASCURA 589, described as the world's first high-power 589-nanometer solid-state vascular laser, offering a new alternative to a market long dominated by liquid PDL lasers.
Additional new products, including a thulium fiber laser for urology, are also under development, advancing diversification within the disease-treatment segment.
The new products' structure, which relies more heavily on consumable sales, is cited as a factor that could contribute to greater revenue stability going forward.
Strata Skin Sciences, the opposing party in the litigation, was delisted from Nasdaq around March 2026 amid financial difficulties, a development that could somewhat ease the uncertainty surrounding the lawsuit.
LaserOptek's U.S. subsidiary has responded proactively, filing counterclaims against Strata and its chief executive in February 2026. The fact that the U.S. FDA previously recognized substantial equivalence between PALLAS Premium and a competing product is cited as evidence supporting the company's position.
Full-year 2025 revenue fell to KRW 25.7 billion from a year earlier, with an operating loss of KRW 12.0 billion and a net loss attributable to owners of KRW 10.7 billion, the largest deficit since listing. Reports from that period also noted the gross margin declining from the mid-40% range to the low 40% range.
Despite the improvement seen in the first half of 2026, the company has not yet fully emerged from its cumulative loss position.
A rights offering conducted between January and April 2026 issued 2.58 million new shares, increasing the total share count. Controlling shareholders subscribed to only about 10% of their allotted shares, reducing their stake and potentially raising market doubts about their commitment to responsible management. The increased share count acts as a dilution factor for future per-share metrics.
The litigation with Strata has not been resolved through a final ruling or settlement even after counterclaims were filed. The resumption of U.S. sales for PALLAS Premium depends on external timing, such as a revision to insurance code descriptions, a variable the company cannot directly control. U.S. FDA approval for VASCURA 589 could also be delayed depending on the filing and review schedule.
The litigation and counterclaims involving Strata remain unresolved, and depending on the eventual ruling, the company could face cost burdens or business constraints. The opposing party's Nasdaq delisting does not fully eliminate litigation risk, and legal defense costs at the U.S. subsidiary level could continue.
Operating cash flow was consistently negative from 2023 through 2025, and the debt ratio rose from 48.9% in 2024 to 64.8% in 2025.
Despite raising external funds through a rights offering, the controlling shareholders' low subscription participation means that funding methods and dilution concerns could resurface if additional capital is needed.
U.S. FDA approval for VASCURA 589, the insurance code revision that will determine whether PALLAS Premium can resume U.S. sales, and certification of new products such as the thulium fiber laser all depend on external agencies' review and revision timelines. Should these schedules slip, the earnings recovery scenario the company has presented could also be delayed.
Investors will watch whether third-quarter 2026 revenue and profitability extend the improvement seen in the first half, particularly the pace of North American sales recovery.
The progress of the U.S. FDA filing for VASCURA 589 and the pace of its domestic sales expansion warrant monitoring.
The status and eventual outcome of the litigation and counterclaims involving Strata Skin Sciences should be tracked.
Confirmation is needed on whether the insurance code description revision that could enable resumed U.S. sales of PALLAS Premium proceeds as expected.
The launch schedule and initial sales performance of new products such as the thulium fiber laser for urology should be reviewed.
LaserOptek saw revenue decline and recorded its largest-ever operating and net losses in 2025 amid litigation with a U.S. competitor, but the first half of 2026 has brought a phase of simultaneous revenue recovery and loss narrowing.
The launch of the new VASCURA 589 product and the potential resumption of U.S. sales for PALLAS Premium are cited as key variables for medium- to long-term earnings improvement.
However, external variables the company cannot directly control, such as the final outcome of the litigation and the timing of insurance code revisions, still remain.
The increase in share count and the low subscription participation by controlling shareholders in the early-2026 rights offering are factors worth noting from a shareholding structure perspective.
Overall, the company appears to be past its earnings trough and entering a recovery phase, while litigation, certification, and financial uncertainties have yet to be fully resolved.
The pace and durability of the recovery will need to be confirmed through future quarterly earnings releases and litigation- or certification-related disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.